Tozinameran
Comirnaty (tozinameran) is an unknown pharmaceutical. Tozinameran was first approved as Comirnaty on 2020-12-21. It has been approved in Europe to treat dna virus infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
134 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | 12 | 34 | 26 | 12 | 23 | 94 | |
| Neoplasms | D009369 | C80 | — | 1 | — | 1 | 2 | 4 | |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | — | 1 | — | 1 |
| Immunosuppression therapy | D007165 | — | — | — | 1 | — | 1 | ||
| Lymphoma | D008223 | C85.9 | — | — | — | 1 | — | 1 | |
| Only child | D009863 | — | — | — | 1 | — | 1 | ||
| Psoriasis | D011565 | EFO_0000676 | L40 | — | — | — | 1 | — | 1 |
| Vesiculobullous skin diseases | D012872 | EFO_1000774 | L10-L14 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | 2 | 2 | — | 2 | 5 | ||
| Sars-cov-2 | D000086402 | — | 2 | 1 | — | 2 | 4 | ||
| Hematologic neoplasms | D019337 | — | — | 1 | — | 1 | 2 | ||
| Immunocompromised host | D016867 | D84.9 | — | 1 | 1 | — | — | 2 | |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | — | — | 1 | — | 1 | 2 | |
| Chronic renal insufficiency | D051436 | N18 | — | 1 | 1 | — | 1 | 2 | |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 1 | 1 | — | 1 | 2 |
| Pneumococcal infections | D011008 | EFO_0000772 | J13 | — | — | 1 | — | — | 1 |
| Non-hodgkin lymphoma | D008228 | C85.9 | — | — | 1 | — | — | 1 | |
| Multiple myeloma | D009101 | C90.0 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | T88.7 | 1 | 1 | — | — | 5 | 6 | |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 2 | — | — | — | 2 |
| Respiratory tract infections | D012141 | J06.9 | 1 | 1 | — | — | 1 | 2 | |
| Infections | D007239 | EFO_0000544 | 1 | 1 | — | — | 1 | 2 | |
| Virus diseases | D014777 | B34 | 1 | 1 | — | — | — | 1 | |
| Rna virus infections | D012327 | 1 | 1 | — | — | — | 1 | ||
| Myeloid leukemia acute | D015470 | C92.0 | 1 | 1 | — | — | — | 1 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 1 | 1 | — | — | — | 1 | |
| Disease | D004194 | EFO_0000408 | R69 | — | 1 | — | — | — | 1 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Human influenza | D007251 | EFO_0007328 | J11.1 | 1 | — | — | — | 1 | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | 1 | 1 | |
| Chronic disease | D002908 | — | — | — | — | 1 | 1 | ||
| Second primary neoplasms | D016609 | — | — | — | — | 1 | 1 | ||
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | — | — | — | — | 1 | 1 | ||
| Vaccine-preventable diseases | D000079263 | — | — | — | — | 1 | 1 | ||
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | — | — | 1 | 1 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TOZINAMERAN |
| INN | tozinameran |
| Description | The Pfizer–BioNTech COVID-19 vaccine (INN: tozinameran), sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with American company Pfizer to carry out clinical trials, logistics, and manufacturing. It is authorized for use in people to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. The vaccine is given by intramuscular injection. It is composed of nucleoside-modified mRNA (modRNA) encoding a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. Initial advice indicated that vaccination required two doses given 21 days apart, but the interval was later extended to up to 42 days in the US, and up to four months in Canada.
|
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4650429 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15696 |
| UNII ID | 5085ZFP6SJ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Comirnaty - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,877 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,145 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more